Insights
Search Results
Client Highlights
10.16.26
Wilson Sonsini Advises Iambic Therapeutics on $150 Million Initial Public Offering
Wilson Sonsini advised Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, in connection with the company’s $150 million initial public offering (IPO). Iambic issued 9,375,000 shares of its common stock at a public offering price of $16 per share, with a 30-day option for the underwriters to purchase up to an additional 1,406,250 shares. Iambic’s common stock began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.”
Client Highlights
10.06.26
Firm Advises Alector on Exclusive Global License Agreement with Genentech
On October 5, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive tiered royalties on net sales and additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
9.18.26
Wilson Sonsini Advises Encoded Therapeutics on $275 Million Series F
On September 9, 2026, Encoded Therapeutics, a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, announced it closed a $275 million Series F financing co-led by GV and another healthcare fund, with participation from ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock. Wilson Sonsini Goodrich & Rosati advised Encoded Therapeutics on the transaction.
Client Highlights
8.18.26
Wilson Sonsini Advises InduPro on $77 Million Series B Financing
On August 12, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
6.02.26
Firm Advises 137 Ventures and BANNER VC on Impulse Space’s $500 Million Series D Financing
On June 2, 2026, Impulse Space, an in-space mobility leader, announced it has raised $500 million in Series D funding, bringing the company’s total capital raised to over $1 billion. The funding will support the company’s hiring and manufacturing growth plans in its efforts to build in-space mobility infrastructure. The funding round was co-led by 137 Ventures and BANNER VC with participation from Founder’s Fund, Lux Capital, and Linse Capital. Wilson Sonsini Goodrich & Rosati advised 137 Ventures and BANNER VC on the transaction.
Client Highlights
2.02.26
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
1.08.26
Firm Advises InduPro on Strategic Investment, Research Collaboration with Sanofi
On December 10, 2025, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a strategic equity investment and research collaboration with Sanofi. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises InduPro on $950 Million Strategic Collaboration with Eli Lilly
On January 7, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company to discover novel oncology treatments using InduPro’s proximity-guided platform. Under the terms of the agreement, InduPro and Eli Lilly will collaborate on up to three targets, for a total deal value of up to approximately $950 million. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
Client Highlights
2.26.25
Firm Advises Investors on Eikon Therapeutics’ $350.7 Million Series D
On February 26, 2025, Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, announced the initial closing of a $350.7 million Series D financing. The round was led by Eikon’s existing investors, with participation from new investors. Wilson Sonsini Goodrich & Rosati represented certain of the investors in the transaction.
The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms, including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.
Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers.
The Wilson Sonsini team that advised the investors on the transaction included Ken Clark, Christina Poulsen, Jacie Valentine, and Jake Morales.
For more information, please see Eikon’s news release.
The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms, including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others.
Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers.
The Wilson Sonsini team that advised the investors on the transaction included Ken Clark, Christina Poulsen, Jacie Valentine, and Jake Morales.
For more information, please see Eikon’s news release.